110 related articles for article (PubMed ID: 3766228)
1. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Plunkett W; Keating M
Adv Exp Med Biol; 1986; 195 Pt B():171-5. PubMed ID: 3766228
[No Abstract] [Full Text] [Related]
2. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
3. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
Plunkett W; Liliemark JO; Estey E; Keating MJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):159-66. PubMed ID: 3589690
[No Abstract] [Full Text] [Related]
4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
5. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
6. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologically directed design of leukemia therapy.
Plunkett W; Heinemann V; Estey E; Keating M
Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Plunkett W; Iacoboni S; Keating MJ
Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
[No Abstract] [Full Text] [Related]
10. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.
Rustum YM; Slocum HK; Wang G; Bakshi D; Kelly E; Buscaglia D; Wrzosek C; Early AP; Preisler H
Med Pediatr Oncol; 1982; 10 Suppl 1():33-43. PubMed ID: 7162465
[TBL] [Abstract][Full Text] [Related]
11. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
Tanaka M; Yoshida S
Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologically directed ara-C therapy for refractory leukemia.
Plunkett W; Iacoboni S; Estey E; Danhauser L; Liliemark JO; Keating MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):20-30. PubMed ID: 4012338
[TBL] [Abstract][Full Text] [Related]
13. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
15. Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
Kubota M; Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Mikawa H
Adv Exp Med Biol; 1989; 253B():363-7. PubMed ID: 2610124
[No Abstract] [Full Text] [Related]
16. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Gandhi V; Plunkett W
Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
[TBL] [Abstract][Full Text] [Related]
17. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
18. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
19. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Eur J Cancer Clin Oncol; 1983 Jul; 19(7):941-4. PubMed ID: 6576907
[TBL] [Abstract][Full Text] [Related]
20. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
